Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.”In the company’s words, NCT04639310 on ClinicalTrials.gov
- Tested for
- Epilepsy (2 trials), Epilepsy in Children (2 trials), Epilepsy; Seizure (2 trials), Disease (2 trials), Brain Diseases (2 trials), Central Nervous System Diseases (2 trials), Nervous System Diseases (2 trials), Epileptic Syndromes (2 trials)
- Main trialPhase 3
- “To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).”In the company’s words, NCT04639310 on ClinicalTrials.gov
- Other names
- ezogabine · retigabine
Other drugs for Epilepsy
- BHV-7000Biohaven · Phase 2/3
- ElsunersenPraxis Precision Medicines · Phase 3
- LP352Longboard Pharmaceuticals · Phase 3
- PRAX-562Praxis Precision Medicines · Phase 3
- VormatroginePraxis Precision Medicines · Phase 3
- EverolimusNovartis · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Terminated | 16 May 2023 | XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy | |
| Phase 3Terminated | 17 Nov 2023 | An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026